当前位置: 首页 >> 检索结果
3973. Opioid analgesia for acute low back pain and neck pain (the OPAL trial): a randomised placebo-controlled trial.
作者: Caitlin M P Jones.;Richard O Day.;Bart W Koes.;Jane Latimer.;Chris G Maher.;Andrew J McLachlan.;Laurent Billot.;Sana Shan.;Chung-Wei Christine Lin.; .
来源: Lancet. 2023年402卷10398期304-312页
Opioid analgesics are commonly used for acute low back pain and neck pain, but supporting efficacy data are scarce. We aimed to investigate the efficacy and safety of a judicious short course of an opioid analgesic for acute low back pain and neck pain.
3977. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.
作者: Julio Rosenstock.;Juan Frias.;Ania M Jastreboff.;Yu Du.;Jitong Lou.;Sirel Gurbuz.;Melissa K Thomas.;Mark L Hartman.;Axel Haupt.;Zvonko Milicevic.;Tamer Coskun.
来源: Lancet. 2023年402卷10401期529-544页
According to current consensus guidelines for type 2 diabetes management, bodyweight management is as important as attaining glycaemic targets. Retatrutide, a single peptide with agonist activity at the glucose-dependent insulinotropic polypeptide (GIP), GLP-1, and glucagon receptors, showed clinically meaningful glucose-lowering and bodyweight-lowering efficacy in a phase 1 study. We aimed to examine the efficacy and safety of retatrutide in people with type 2 diabetes across a range of doses.
3978. Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial.
作者: Vanita R Aroda.;Jens Aberle.;Lars Bardtrum.;Erik Christiansen.;Filip K Knop.;Sanaz Gabery.;Sue D Pedersen.;John B Buse.
来源: Lancet. 2023年402卷10403期693-704页
Once-daily oral semaglutide is an effective type 2 diabetes treatment. We aimed to investigate a new formulation of oral semaglutide at higher investigational doses versus the approved 14 mg dose in adults with inadequately controlled type 2 diabetes.
3979. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial.
作者: Filip K Knop.;Vanita R Aroda.;Ruben D do Vale.;Thomas Holst-Hansen.;Peter N Laursen.;Julio Rosenstock.;Domenica M Rubino.;W Timothy Garvey.; .
来源: Lancet. 2023年402卷10403期705-719页
We assessed the efficacy and safety of the oral glucagon-like peptide-1 analogue, semaglutide 50 mg, taken once per day versus placebo for the treatment of overweight or obesity in adults without type 2 diabetes.
|